Introduction
Levodopa + Carbidopa (CR tablet) is a combination medication used to manage the symptoms of Parkinson's disease and Parkinsonism. Levodopa, a precursor to dopamine, helps replenish the brain's dopamine levels, which are deficient in Parkinson's disease. Carbidopa inhibits the peripheral conversion of levodopa to dopamine, thereby increasing the amount of levodopa that reaches the brain and reducing peripheral side effects.
Uses
This combination medication is primarily used for:
- Treating symptoms of Parkinson's disease, such as tremors, rigidity, and bradykinesia (slowness of movement).
- Managing Parkinsonism resulting from other causes or secondary conditions.
Mechanism of Action
Levodopa is converted to dopamine in the brain, which helps to restore the depleted dopamine levels associated with Parkinson's disease. Carbidopa acts as an inhibitor of the enzyme aromatic L-amino acid decarboxylase, which prevents the conversion of levodopa to dopamine in the peripheral tissues. This helps to enhance the therapeutic effect of levodopa and reduce side effects like nausea and vomiting.
How Long Does It Take to Work?
Levodopa + Carbidopa CR tablets typically start showing improvement in symptoms within 30 to 60 minutes of administration. However, the full therapeutic effects may take several weeks to achieve, as the body adjusts to the medication.
Absorption
Levodopa is absorbed from the gastrointestinal tract, primarily in the duodenum and jejunum. The CR (controlled-release) formulation provides a slower and more sustained release of levodopa, which helps in maintaining more stable blood levels of the drug and provides prolonged therapeutic effects.
Route of Elimination
Levodopa and its metabolites are primarily eliminated through the urine. Some levodopa is also metabolized in the liver. Carbidopa is mainly excreted in the urine as well.
Dosage
Patients currently treated with conventional levodopa/decarboxylase inhibitor combinations: Dosage with Levodopa-Carbidopa prolonged-release tablet should be substituted initially at an amount that provides no more than approximately 10% more levodopa per day when higher dosages are given (more than 900 mg per day). The dosing interval between doses should be prolonged by 30 to 50% at intervals ranging from 4 to 12 hours. It is recommended to give the smaller dose, if divided doses are not equal, at the end of the day. The dose needs to be titrated further depending on clinical response, as indicated below under 'Titration'. Dosages that provide up to 30% more levodopa per day may be necessary. A guide for substitution of Levodopa Carbidopa prolonged-release tablet treatment for conventional levodopa/decarboxylase inhibitor combinations is shown in the table below:Guideline for conversion from conventional Levodopa/Carbidopa tablet to Levodopa-Carbidopa prolonged-release tablet:
Conventional tablet: Daily Dosage of Levodopa 300-400 mg
- Controlled Release tablet: Daily Dosage of Levodopa 400 mg. Dosage Regimen: 1 tablet 2x daily.
- Controlled Release tablet: Daily Dosage of Levodopa 600 mg. Dosage Regimen: 1 tablet 3x daily.
- Controlled Release tablet: Daily Dosage of Levodopa 800 mg. Dosage Regimen: 4 tablets in 3 or 4 divided doses.
- Controlled Release tablet: Daily Dosage of Levodopa 1000 mg. Dosage Regimen: 5 tablets in 3 or more divided doses.
- Controlled Release tablet: Daily Dosage of Levodopa 1200 mg. Dosage Regimen: 6 tablets in 3 or more divided doses.
- Controlled Release tablet: Daily Dosage of Levodopa 1400 mg. Dosage Regimen: 7 tablets in 3 or more divided doses.
- Controlled Release tablet: Daily Dosage of Levodopa 1600 mg. Dosage Regimen: 8 tablets in 3 or more divided doses.
The dosage of Levodopa + Carbidopa CR tablets is individualized based on patient response and tolerance. Typical dosages include:
- Initial dosage: Often starts at 100 mg of levodopa and 25 mg of carbidopa, taken 1-2 times daily.
- Maintenance dosage: Can range from 200-1600 mg of levodopa daily, divided into 2-3 doses, adjusted based on individual needs.
Dosage should be tailored to each patient’s requirements, with adjustments made by a healthcare provider based on efficacy and tolerability.
Administration
Levodopa + Carbidopa CR tablets should be administered orally. It is recommended to take the tablets with food to minimize gastrointestinal side effects. The CR formulation allows for once or twice daily dosing depending on the patient’s needs and response.
Side Effects
Common side effects may include:
- Nausea
- Vomiting
- Dizziness
- Dry mouth
- Orthostatic hypotension (low blood pressure upon standing)
Serious side effects may include:
- Uncontrolled movements (dyskinesias)
- Hallucinations
- Severe mood changes
Toxicity
Symptoms of toxicity can include severe nausea, vomiting, cardiovascular effects, and severe dyskinesias. Immediate medical attention is required if overdose symptoms are present.
Precautions
Precautions should be observed in individuals with:
- Severe cardiovascular disease
- History of psychosis
- Peptic ulcer disease
- Glaucoma
Regular monitoring of blood pressure, heart rate, and other relevant health parameters is advisable during treatment.
Interaction
Levodopa + Carbidopa CR tablets can interact with several medications, including:
- Antidepressants (e.g., MAO inhibitors) which may enhance side effects.
- Antihypertensives which might have altered effects.
- Other central nervous system depressants (e.g., sedatives, antipsychotics).
Disease Interaction
Use cautiously in patients with:
- History of melanoma or suspicious skin lesions
- Severe hepatic impairment
- Active peptic ulcer disease
Drug Interaction
Drug interactions may occur with:
- Certain antihypertensives and diuretics.
- Anticholinergic drugs which may affect levodopa’s effectiveness.
Food Interactions
High-protein meals may interfere with the absorption of levodopa. It is often recommended to take the medication with a low-protein diet or to space out protein intake throughout the day to enhance drug absorption.
Pregnancy Use
Levodopa + Carbidopa is categorized as a pregnancy category C drug. This means that risk cannot be ruled out. The medication should be used during pregnancy only if the potential benefits justify the potential risks to the fetus.
Lactation Use
Levodopa and carbidopa are excreted in breast milk. It is recommended to either avoid breastfeeding or use the medication only if the benefits outweigh the risks. Consultation with a healthcare provider is necessary for guidance.
Acute Overdose
Acute overdose may result in severe nausea, vomiting, abnormal movements, and cardiovascular effects. Immediate medical attention is required in cases of overdose.
Contraindication
Levodopa + Carbidopa CR tablets are contraindicated in individuals with:
- Hypersensitivity to levodopa, carbidopa, or any components of the formulation.
- Use of non-selective MAO inhibitors within the past 14 days.
Use Direction
Administer Levodopa + Carbidopa CR tablets as prescribed by your healthcare provider. Adhere to the dosage instructions and report any side effects or unusual symptoms promptly. Do not modify the dose or stop the medication without consulting your healthcare provider.
Storage Conditions
Store at room temperature, away from moisture and heat. Keep out of reach of children. Do not use beyond the expiration date printed on the packaging.
Volume of Distribution
The volume of distribution for levodopa is approximately 2-4 L/kg, reflecting its distribution throughout the body and brain, where it is converted into dopamine.
Half Life
The half-life of levodopa is approximately 1-2 hours. The CR formulation allows for prolonged release, providing sustained therapeutic effects. Carbidopa also has a half-life of about 1-2 hours.
Clearance
Levodopa is primarily cleared through the kidneys, with about 70-80% excreted in the urine as metabolites. Carbidopa is similarly cleared through the kidneys.
